scFv(TACSTD2)-CD28-41BB-CD3zeta CAR-T Lentivirus

The scFv(TACSTD2)-CD28-41BB-CD3zeta CAR-T Lentivirus is a specialized gene delivery vector designed to engineer T cells for the targeted elimination of cells expressing Tumor-Associated Calcium Signal Transducer 2 (TACSTD2), commonly known as TROP2. This third-generation chimeric antigen receptor (CAR) construct features a high-affinity single-chain variable fragment (scFv) that specifically recognizes the extracellular domain of TROP2. The intracellular signaling component is engineered with a tandem arrangement of the CD28 and 4-1BB (CD137) co-stimulatory domains, linked to the CD3zeta activation tail. This dual-signaling configuration is intended to mimic natural T-cell activation more closely, promoting enhanced proliferative capacity, metabolic stability, and sustained effector function compared to earlier generations. The lentiviral backbone facilitates high-efficiency transduction and stable integration of the CAR transgene into the host genome, ensuring robust and persistent expression across the T-cell population.

This lentiviral product is a critical tool in the development of immunotherapies for a broad spectrum of epithelial malignancies, including triple-negative breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. Because TROP2 is significantly overexpressed in these solid tumors but has limited expression in healthy tissues, this CAR-T construct is extensively used in preclinical studies to validate target-specific cytotoxicity and safety profiles. Researchers utilize the lentivirus to generate CAR-T cells for use in co-culture killing assays, phenotypic analysis via flow cytometry, and longitudinal monitoring in humanized mouse models. Beyond basic efficacy testing, the inclusion of both CD28 and 4-1BB domains makes it an ideal model for studying the signaling dynamics of T-cell exhaustion and the optimization of CAR-T persistence within the immunosuppressive tumor microenvironment. It serves as a foundational resource for advancing cell-based therapies toward clinical translation.